Bronchiectasis With Pseudomonas Aeruginosa Colonization
Conditions
Brief summary
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
Detailed description
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA. This Phase II study aims to assess the efficacy, safety, and PK of AZD0292 administered IV, as compared to placebo in participants 18 years of age and older. The population of this study will be Chinese NCFBE patients with frequent pulmonary exacerbations due to chronic PsA airway colonization. These PsA associated pulmonary exacerbations contribute to a decline in lung function, impair quality of life and increase mortality, highlighting the urgent need for effective therapeutic options.
Interventions
DRUGAZD0292
AZD0292 administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
OTHERPlacebo
Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant must be ≥ 18 years of age at the time of signing the informed consent/assent. * Weight ≥ 35 kg. * Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility. * Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics * Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization * Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening. * Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening * Presence of culture positive PsA in sputum at least within 5 weeks of randomization. Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study. * Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
Exclusion criteria
* Primary lung diagnosis other than bronchiectasis * Evidence of active tuberculosis or active nontuberculous mycobacteria being treated or requiring treatment. Participants currently receiving treatment for active TB or nontuberculous mycobacteria may be considered after completion of an appropriate course of therapy * Evidence of an active allergic bronchopulmonary aspergillosis being treated or requiring treatment * Need for long term supplemental oxygen. Oxygen use for ambulation and relief of breathlessness after exercise is allowed * Malignancy, current or within the previous 5 years, except for stable prostate cancer, adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than one year prior to enrolment * AIDS or Advanced human immunodeficiency virus disease (CD4 count of \< 200 cells/mm3) * History of severe adverse reaction associated with a mAb, and/or history of severe allergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenaline or hospitalization), and/or history of immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody administration * Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors, which are newly initiated within the 3 months prior to screening * Chronic immunosuppressive therapy (including prednisolone \> 5 mg or equivalent) newly initiated within the last 3 months * Receipt of investigational products indicated for the treatment or prevention of bronchiectasis exacerbations or expected receipt during the study * Participation with a study intervention used within the last 30 days or 5 half-lives of the investigational product from the other clinical study, whichever is longer, prior to screening. * Female participants who are pregnant, lactating, or WOCBP and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Annualized rate of exacerbations over a variable follow-up time | Min 28 weeks, max 52 weeks | To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first moderate or severe exacerbation | Time Frame: Through study completion (Final Dose +24 weeks) | To evaluate the effect of AZD0292 compared to placebo on time to first pulmonary exacerbation in participants with NCFBE and chronic colonization with PsA. |
| Serum PK Concentrations | At specified timepoints between Week 0 and Final Dose +12 weeks | To evaluate the PK of IV doses of AZD0292 in participants with bronchiectasis and chronic colonization with PsA |
| Incidence of ADA and ADA titers to AZD0292 | At specified timepoints between Week 0 and Final Dose +12 weeks | To evaluate the immunogenicity of IV doses of AZD0292 in participants with bronchiectasis and chronic colonization with PsA |
| Incidence of AEs, SAEs, AESIs and MAAEs | Occurrence of AEs; first dose through 12 weeks after last study intervention administration. Occurrence of SAEs, AESIs, and MAAEs; through study completion (Final Dose+24 weeks) | To assess the safety of AZD0292 compared with placebo in participants with bronchiectasis and chronic colonization with PsA |
| Annualized rate of severe exacerbations over a variable follow-up time | Min 28 weeks, max 52 weeks | To evaluate the effect of AZD0292 compared to placebo on severe exacerbations in participants with NCFBE and chronic colonization with PsA |
| Change from baseline in SGRQ score | Over the observation period (Week 0 to Last Dose+4 weeks) | To evaluate the effect of AZD0292 compared to placebo on quality of life, as assessed by SGRQ over the observation period. |
| Change from baseline in QoL-B-RSS | Over the observation period (Week 0 to Last Dose+4 weeks) | To evaluate the effect of AZD0292 compared to placebo on quality of life, as assessed by QoL-B-RSS over the observation period |
Countries
China
Contacts
CONTACTAstraZeneca Clinical Study Information Center
Outcome results
None listed